Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-08-02
Based on 441 first isolates · GER · Febrile UTI / pyelonephritis · 2025-08-03 → 2026-08-02
Geriatrics
Per-organism detail: GER urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
piperacillin-tazobactam 82 % (78 %–85 %)
Keep for severe or hospital-onset infections.
Not covered: Enterococcus faecalis (10 %), Staphylococcus aureus (3 %), Escherichia coli (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
85 %
97 %
n = 38
nitrofurantoin NIT
trend · Escherichia coli not for this site
84 %
89 %
n = 38
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
95 %
n = 38
ciprofloxacin CIP
trend · Escherichia coli
79 %
92 %
n = 38
mecillinam MEC
trend · Escherichia coli not for this site
78 %
92 %
n = 38
ceftriaxone CRO
trend · Escherichia coli
76 %
89 %
n = 38
73 %
82 %
n = 38
trimethoprim TMP
trend · Escherichia coli not for this site
67 %
71 %
n = 38
48 %
53 %
n = 38
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
3 %
n = 38
5 %
3 %
n = 38
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
3 %
n = 38

Most likely organisms for this profile

Escherichia coli
59 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
10 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
5 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.